NCT05733546Phase 2Active not recruiting

A Phase II, Multicentre, Randomised, Double-blind, Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of COMP360 in Participants With Recurrent Major Depressive Disorder

Study sponsor: COMPASS Pathways

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2025-09Estimated
Enrollment · participants102Actual
Source updated2025-08-19Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview